288 related articles for article (PubMed ID: 32443539)
1. Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan.
Raja AM; Ciociola E; Ahmad IN; Dar FS; Naqvi SMS; Moaeen-Ud-Din M; Kaukab Raja G; Romeo S; Mancina RM
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443539
[TBL] [Abstract][Full Text] [Related]
2. Relevance of
Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
4. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
Lin YC; Chang PF; Chang MH; Ni YH
Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
Lin YC; Chang PF; Chang MH; Ni YH
Am J Clin Nutr; 2014 Apr; 99(4):869-74. PubMed ID: 24477042
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
[TBL] [Abstract][Full Text] [Related]
8. Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis.
Beaudoin JJ; Liang T; Tang Q; Banini BA; Shah VH; Sanyal AJ; Chalasani NP; Gawrieh S
Alcohol Clin Exp Res; 2021 Apr; 45(4):709-719. PubMed ID: 33616244
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
[TBL] [Abstract][Full Text] [Related]
11. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.
Zusi C; Mantovani A; Olivieri F; Morandi A; Corradi M; Miraglia Del Giudice E; Dauriz M; Valenti L; Byrne CD; Targher G; Maffeis C
Dig Liver Dis; 2019 Nov; 51(11):1586-1592. PubMed ID: 31255630
[TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study).
Käräjämäki AJ; Hukkanen J; Kauma H; Kesäniemi YA; Ukkola O
Scand J Clin Lab Invest; 2020; 80(2):106-113. PubMed ID: 31851849
[TBL] [Abstract][Full Text] [Related]
13. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.
Mancina RM; Dongiovanni P; Petta S; Pingitore P; Meroni M; Rametta R; Borén J; Montalcini T; Pujia A; Wiklund O; Hindy G; Spagnuolo R; Motta BM; Pipitone RM; Craxì A; Fargion S; Nobili V; Käkelä P; Kärjä V; Männistö V; Pihlajamäki J; Reilly DF; Castro-Perez J; Kozlitina J; Valenti L; Romeo S
Gastroenterology; 2016 May; 150(5):1219-1230.e6. PubMed ID: 26850495
[TBL] [Abstract][Full Text] [Related]
14. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
[TBL] [Abstract][Full Text] [Related]
15. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
[TBL] [Abstract][Full Text] [Related]
16. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits.
Kitamoto A; Kitamoto T; Nakamura T; Ogawa Y; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Nakao K; Sekine A; Chayama K; Nakajima A; Hotta K
Endocr J; 2014; 61(7):683-9. PubMed ID: 24785259
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
[TBL] [Abstract][Full Text] [Related]
18.
Basyte-Bacevice V; Skieceviciene J; Valantiene I; Sumskiene J; Petrenkiene V; Kondrackiene J; Petrauskas D; Lammert F; Kupcinskas J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875804
[TBL] [Abstract][Full Text] [Related]
19. Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program.
Serper M; Vujkovic M; Kaplan DE; Carr RM; Lee KM; Shao Q; Miller DR; Reaven PD; Phillips LS; O'Donnell CJ; Meigs JB; Wilson PWF; Vickers-Smith R; Kranzler HR; Justice AC; Gaziano JM; Muralidhar S; Pyarajan S; DuVall SL; Assimes TL; Lee JS; Tsao PS; Rader DJ; Damrauer SM; Lynch JA; Saleheen D; Voight BF; Chang KM;
PLoS One; 2020; 15(8):e0237430. PubMed ID: 32841307
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.
Liao S; An K; Liu Z; He H; An Z; Su Q; Li S
J Clin Lab Anal; 2022 Sep; 36(9):e24626. PubMed ID: 35881683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]